The Middle East and Africa In-Vitro Fertilization Market size is expected to reach USD 0.55 billion by 2027 from USD 0.26 billion in 2022, growing at a CAGR of 16.64% from 2022 to 2027.
The high rate of healthcare GDP, increase in the average age of the first child, drop-in infertility rates, rising cases of young people suffering from non-communicable diseases such as polycystic ovary syndrome, diabetes, increasing incidence of obesity, favorable fertility tourism, and government initiatives are the factor responsible for the positive growth of the MEA IVF market. However, globally, the birth rate is declining due to various factors such as the increasing age-related infertility and preference for late marriage and children. According to the United Nations, the UAE's current birth rate in 2022 is 10,112 births per 1,000 people, down 0.88% from 2020. In 2020, the regional birth rate was at 10,200 births per 1,000 people, down by 0.88% from the year 2019. While in 2019, the birth rate was recorded at 10,291 births per 1,000 people, down 0.87% from 2018. Thus, the decline in the birth rate can be attributed to rising in infertility, leading to a significant increase in demand for IVF treatments for both men and females.
In women, the chances of conceiving decrease after age 32, and by the age of 40, fertility rates are halved; likewise, in men between the ages of 20 and 80, semen volume and sperm motility decrease. Therefore, women who delay pregnancy are at increased risk of low birth weight, miscarriage, fetal abnormalities, premature labor, still birth, prolonged labor, and maternal morbidity. According to a new report, the fertility rate across the globe was at 10%, and the percentage was at a high of 15% or more in the Middle East and African region. Also, infertility in males is growing with an increased number of nearly 50%, and these cases are due to lifestyle, lack of exercise, diabetes, obesity, and genetics-related factors. All the factors mentioned above are anticipated to drive the MEA IVF market for the next few years.
According to a study from the Advanced Fertility Center in Chicago, 1 in 4 women is infertile by 35. The study indicates that the pregnancy rate gradually declines in your 30s and drops sharply over the past 30 and 40 years. Additionally, it can be noted that the success rate of a single IVF cycle is limited, where many couples try multiple processes. Decreasing the success rates of IVF treatment procedures with increasing patient age is a significant challenge for fertility treatment technologies. Additionally, complications associated with IVF treatment and inadequate reimbursement options will restraint the market during the forecast period.
This research report on the Middle East and Africa In-vitro fertilization market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By Instruments:
By Technology:
By End Users:
By Country:
Geographically, the Saudi Arabian market is expected to be the largest market share in the MEA IVF market. This market growth can be attributed to the decline in the birth rate, the growing number of government-backed fertility clinics and infertility services, and increased product launches are expected to boost the regional market. Saudi Arabia's current birth rate in 2022 is 16,630 births per 1,000 people, a decrease of 2.73% from 2020. While in the year 2020, the birth rate was at 17,097 births per 1,000 people, a reduction of 2.65% compared to 2019. The markets are anticipated to grow and gather new opportunities with collaborations between international players and the regional government for healthcare awareness.
In the UAE, the regional market will grow with the highest CAGR during the projected period, owing to increasing rates of obesity and polycystic ovary syndrome, delayed marriages, better reimbursement policies, and increased IVF tourism. According to a recent report, medical tourism represents 12 to 16% of the volume of IVF patients. Additionally, the growing number of product launches and medications are expected to boost the UAE IVF market.
KEY MARKET PLAYERS:
Companies playing a notable role in the MEA In-Vitro Fertilization Market covered in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Reagents and Media
5.2.1 Introduction
5.2.2 Embryo Culture Media
5.2.3 Cryopreservation Media 5.2.2.1 Autologous Cell-Based Products
5.2.4 Sperm Processing Media 5.2.2.2 Allogeneic Cell-Based Products
5.2.5 Ovum Processing Media
5.3 Instruments
5.3.1 Introduction
5.3.2 Imaging Systems
5.3.3 Sperm Separation Systems
5.3.4 Ovum Aspiration Pumps
5.3.5 Incubators
5.3.6 Micromanipulator Systems
5.3.7 Cryosystems
5.3.8 Other Instruments (Gas Analyzers, Laser Systems, Accessories)
5.4 Technology
5.3.1 Introduction
5.3.2 Intra-Cytoplasmic Sperm Injection (ICSI)
5.3.3 Pre-Implantation Genetic Diagnosis (PGD)
5.3.4 Frozen Embryo Transfer/Replacement (FET/FER)
5.3.5 Other Technologies
5.5 End Users
5.4.1 Introduction
5.4.2 Fertility and Surgical Centers
5.4.3 Hospitals and Research Laboratories
5.4.4 Cryobanks
6.5.1 Introduction
6.5.2 Middle East
6.5.2 South Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 CooperSurgical, Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cook Medical, Inc. (U.S.)
8.3 Irvine Scientific (U.S.)
8.4 Vitrolife AB (Sweden)
8.5 Thermo Fisher Scientific, Inc. (U.S.)
8.6 EMD Serono, Inc. (U.S.)
8.7 Genea Limited (Australia)
8.8 ESCO Micro Pte. Limited (Singapore)
8.9 IVFtech ApS (Denmark)
8.10 The Baker Company, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
